Navigation Links
SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application
Date:3/11/2011

BOTHELL, Wash., March 11, 2011 /PRNewswire/ -- SCOLR Pharma, Inc. (OTC Bulletin Board: SCLR) today announced it has received a letter from the Food and Drug Administration (FDA) identifying deficiencies regarding its Abbreviated New Drug Application (ANDA) for extended-release pseudoephedrine.  

The Company said the letter identified a number of concerns that the FDA had with the conduct of the bioequivalence study submitted by SCOLR to support the application.  The deficiencies cited relate to the design and conduct of the study.  None of the issues raised relate to the product formulation.  Due to these deficiencies, the agency said it is unable to approve the ANDA application at this time.

Stephen J. Turner, SCOLR Pharma's President and CEO, said: "Although we are extremely disappointed with this situation, we are currently evaluating the deficiencies identified by the FDA to determine the most appropriate course of action.  We remain confident in our pseudoephedrine product and intend to rectify the FDA's concerns."

About SCOLR Pharma:Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/.

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning next steps and intended actions with respect to our pseudoephedrine product. These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including our ability to fund any additional or revised trial studies required to address the FDA's deficiency notice, and the time required for any additional or revised studies.  Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission, including the "Risk Factors" set forth in our Annual Report on Form 10-K, as supplemented by our quarterly reports on Form 10-Q. Such filings are available on our website or at www.sec.gov. You are cautioned that such statements are not guarantees of future performance and that actual result or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstance.Contacts:Investor Relations: SCOLR Pharma, Inc. 425.368.1050
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SCOLR Pharma, Inc. Retains Nicholas Hall & Company
2. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
3. SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange
4. SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
5. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
6. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
7. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
8. SCOLR Pharma, Inc. Licenses Dietary Supplements
9. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
10. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
11. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... July 10, 2017 Locus Biosciences Inc. today ... support the development of CRISPR-Cas3 antimicrobial therapeutics. Financing for ... leading Chinese Internet services provider, and joined by the ... infectious disease product programs targeting antibiotic resistant infections and ... Founded by Dr. Rodolphe Barrangou and Dr. ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife"), today announced that it has reached ... holder and largest shareholder, to modify its existing credit ... to the modification, WAVI agreed to exchange its existing ...
(Date:6/27/2017)... TEL AVIV, Israel , June 27, 2017 /PRNewswire/ ... a specialty clinical-stage pharmaceutical company specializing in the development ... ring The Nasdaq Stock Market Opening Bell in ... 28, 2017 in honor of its initial public offering ... Nasdaq Capital Market in March 2017. Dr. ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... Hospital M&A activity slowed ... . The number of hospital acquisitions rose to 23 in the second quarter, up ... up 15% from the 20 announced deals in the year-ago second quarter. Only four ...
(Date:7/21/2017)... NJ (PRWEB) , ... July 21, 2017 , ... ... has received a $5,000 grant from the C. R. Bard Foundation, ... Day Center at Somerset Hills , a service available through the nonprofit home ...
(Date:7/21/2017)... ... , ... West Dermatology is pleased to announce the newest addition to their ... Vu will join West Dermatology’s large network of medical and cosmetic dermatology practices, bringing ... and more. She graduated from the University of Florida College of Medicine Physician Assistant ...
(Date:7/20/2017)... ... , ... TransPixel Volume 2 is a set of transitions that create a ... isolates horizontal and vertical lines of pixels and sorts their pixels by darkness, brightness, ... and can be changed using a drop-down menu. Create amazing and artistic transitions using ...
(Date:7/20/2017)... ... July 20, 2017 , ... Coats Rose, P.C. , ... announce their expansion to the Midwest with the establishment of the firm’s new ... Bell, and of counsels, John Peck and Robert Bruns, will establish and anchor ...
Breaking Medicine News(10 mins):